As filed with the Securities and Exchange Commission on November 23, 2004
Registration No. 333-102259
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
-------------------------
Post-Effective Amendment No. 1 to Form F-3
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
-------------------------
TEVA PHARMACEUTICAL INDUSTRIES LIMITED TEVA PHARMACEUTICAL FINANCE B.V.
(Exact name of Registrant as specified in (Exact name of Registrant as specified
its charter and translation of Registrant's in its charter)
name into English)
Israel N.A. Netherlands Antilles N.A.
(State or other (I.R.S. Employer (State or other (I.R.S.
jurisdiction of Identification jurisdiction of Employer
incorporation or No.) incorporation or Identification
organization) organization) No.)
5 Basel Street c/o MeesPierson Trust (Curacao) N.V.
P.O. Box 3190 Berg Ararat 1
Petach Tikva 49131 Israel Curacao, Netherlands Antilles
972-3-926-7267 599-9-463-9113
(Address, including zip code, and telephone (Address, including zip code, and telephone
number, number,
including area code, including area code,
of Registrant's principal executive offices) of Registrant's principal executive offices)
Teva Pharmaceuticals USA, Inc.
1090 Horsham Road
North Wales, Pennsylvania 19454
Attention: William A. Fletcher
(215) 591-3000
(Name, address, including zip code, and telephone number, including area
code, of agent for service)
with copies to:
PETER H. JAKES, Esq.
JEFFREY S. HOCHMAN, Esq.
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, New York 10019
(212) 728-8000
-------------------------
DEREGISTRATION OF UNSOLD SECURITIES
-------------------------
$86,055,000 aggregate principal amount of 0.375% Convertible Senior
Debentures due 2022 (the "Debentures") of Teva Pharmaceutical Finance B.V., the
guarantee thereof by Teva Pharmaceutical Industries Limited ("Teva") and
4,011,982 American Depositary Receipts ("ADRs") evidencing American Depositary
Shares, each representing one ordinary share, par value 0.10 NIS ("Ordinary
Shares"), of Teva, into which the Debentures are convertible (giving effect to
the two-for-one stock splits of the Ordinary Shares in December 2002 and in June
2004) previously registered for sale to the public by selling securityholders
under this Registration Statement are hereby withdrawn from registration. Such
Debentures, guarantee and ADRs represent all the securities remaining unsold
under this Registration Statement.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the
Registrant has duly caused this Post-Effective Amendment No. 1 to the
Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in Curacao, Netherlands Antilles, on November 23, 2004.
TEVA PHARMACEUTICAL FINANCE B.V.
By: MEESPIERSON TRUST (CURACAO) N.V.,
its sole managing director
By /s/ Steven Melkman
----------------------------
Name: Steven Melkman
Title: Authorized Signatory
By /s/ Lucie de Jong
----------------------------
Name: Lucie de Jong
Title: Authorized Signatory
Pursuant to the requirements of the Securities Act of 1933, as amended,
this Post-Effective Amendment No. 1 to the Registration Statement has been
signed by the following persons in the capacities and on the dates indicated.
Name Title(s) Date
--------------------------------- --------------------------------- ---------------------------------
MEESPIERSON TRUST (CURACAO) N.V. Sole Managing Director
(Principal Executive Officer;
Principal Financial Officer and
Principal Accounting Officer)
By: /s/ Steven Melkman November 23, 2004
---------------------------------
By: Steven Melkman
Title: Authorized Signatory
By: /s/ Lucie de Jong November 23, 2004
---------------------------------
By: Lucie de Jong
Title: Authorized Signatory
--------------------------------- Managing Director of November __, 2004
Bart Gerard Jules Deconinck MeesPierson Trust (Curacao) N.V.,
sole managing director of Teva
Pharmaceutical Finance B.V.
/s/ Robertus Johannes Gerardus Statutory Director of November 23, 2004
--------------------------------- MeesPierson Trust (Curacao) N.V.,
Antonius Bremer sole managing director of Teva
--------------------------------- Pharmaceutical Finance B.V.
Robertus Johannes Gerardus
Antonius Bremer
/s/ Sisulawatie Antonius Soedhoe Statutory Director of November 23, 2004
--------------------------------- MeesPierson Trust (Curacao) N.V.,
Sisulawatie Antonius Soedhoe sole managing director of Teva
Pharmaceutical Finance B.V.
/s/ Gregory Elias Managing Director of November 23, 2004
--------------------------------- MeesPierson Trust (Curacao) N.V.,
Gregory Elias sole managing director of Teva
Pharmaceutical Finance B.V.
/s/ William A. Fletcher Authorized U.S. Representative November 23, 2004
---------------------------------
William A. Fletcher
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the
Registrant has duly caused this Post-Effective Amendment No. 1 to the
Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Petach Tikva, Israel, on November 23, 2004.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
By: /s/ Israel Makov
-------------------------------------
Israel Makov
President and Chief Executive Officer
Pursuant to the requirements of the Securities Act of 1933, as amended,
this Post-Effective Amendment No. 1 to Registration Statement has been signed by
the following persons in the capacities and on the dates indicated.
Name Title(s) Date
--------------------------------- --------------------------------- ---------------------------------
* Chairman and Director November 23, 2004
---------------------------------
Eli Hurvitz
/s/ Israel Makov President and Chief Executive November 23, 2004
--------------------------------- Officer
Israel Makov (Principal Executive Officer)
/s/ Dan S. Suesskind Chief Financial Officer November 23, 2004
--------------------------------- (Principal Financial Officer and
Dan S. Suesskind Principal Accounting Officer)
* Director November 23, 2004
---------------------------------
Ruth Cheshin
Director November __, 2004
---------------------------------
Abraham E. Cohen
* Director November 23, 2004
---------------------------------
Leslie Dan
* Director November 23, 2004
----------------------------
Amir Elstein
* Director November 23, 2004
---------------------------------
Prof. Meir Heth
* Director November 23, 2004
---------------------------------
Prof. Moshe Many
* Director November 23, 2004
---------------------------------
Dr. Leora Meridor
* Director November 23, 2004
---------------------------------
Dr. Max Reis
Director November __, 2004
----------------------------
Carlo Salvi
* Director November 23, 2004
---------------------------------
Prof. Michael Sela
* Director November 23, 2004
---------------------------------
Dov Shafir
Director November __, 2004
---------------------------------
Prof. Gabriela Shalev
Director November __, 2004
---------------------------------
Harold Snyder
/s/ William A. Fletcher Authorized U.S. Representative November 23, 2004
---------------------------------
William A. Fletcher
*By: /s/ Dan S. Suesskind
---------------------------
Dan S. Suesskind
Attorney-in-Fact